INTRODUCTION
============

As persistently high levels of hepatitis B virus (HBV) replication are closely associated with an increased risk for liver cirrhosis and hepatocellular carcinoma (HCC),[@b1-gnl-13-197] replication-suppressing antiviral therapy (AVT) is the mainstay of current management for chronic hepatitis B (CHB).[@b2-gnl-13-197],[@b3-gnl-13-197] This is strongly supported by a landmark randomized placebo-controlled trial by Liaw *et al*.,[@b4-gnl-13-197] which stratified CHB patients with advanced fibrosis or cirrhosis into lamivudine and placebo arms and found a significant benefit against HCC development in the lamivudine arm. Similarly, several subsequent meta-analyses have confirmed the beneficial influence of AVT in the long-term outcomes of CHB patients.[@b5-gnl-13-197],[@b6-gnl-13-197]

Due to this proven benefit of AVT against HCC development, no randomized placebo-controlled trials of drugs with a high genetic barrier, including entecavir or tenofovir, are available. Accordingly, recent studies have adopted cohorts of untreated historical controls to investigate the influence of drugs with a high genetic barrier on HCC development. Among several historical control-matched studies,[@b7-gnl-13-197]--[@b10-gnl-13-197] a large, retrospective-prospective study by Wong *et al*.[@b7-gnl-13-197] included 1,446 patients treated with entecavir and 424 untreated historical controls. In this study, entecavir significantly reduced the 5-year incidence rates of HCC (hazard ratio \[HR\]=0.55), hepatic events (HR=0.51), liver-related mortality (HR=0.26), and all-cause mortality (HR=0.34) in patients with liver cirrhosis but not in the entire patient population.[@b7-gnl-13-197]

Although randomized, placebo-controlled trials and historical control-matched studies have shown that AVT reduces the risk of HCC development in CHB patients (particularly those with liver cirrhosis), the status of HBV infection is inevitably heterogeneous within CHB cohorts at any given time in the real-world setting. CHB patients with a high viral load but who are in the immune tolerant phase or with low viral load in the inactive carrier phase do not require AVT, whereas those in the immune clearance or reactivation phases require AVT to prevent disease progression. Thus, there is a possibility that the different clinical characteristics of each HBV status can potentially bias the influence of AVT on HCC development if untreated cohorts or historical controls are not available. Indeed, a recent study by Cho *et al*.[@b11-gnl-13-197] showed that HCC risk remained higher in patients who even achieved complete virological remission than in patients with an inactive carrier status.[@b11-gnl-13-197] Furthermore, another recent study by Park *et al*.[@b12-gnl-13-197] showed that AVT was independently associated with a higher risk of HCC development due to the different baseline characteristics between CHB patients treated with AVT and those who did not receive AVT.

Thus, in this multicenter retrospective study, we investigated the influence of AVT as well as of HBV-related variables on the risk of HCC development in a cohort with heterogeneous HBV status.

MATERIALS AND METHODS
=====================

1. Patients
-----------

From January 2013 to December 2013, consecutive CHB patients from two institutions (Severance Hospital, Yonsei University and CHA Bundang Medical Center, CHA University) were considered eligible for this study. CHB was defined as the persistent presence of serum hepatitis B surface antigen (HBsAg) for more than 6 months. The exclusion criteria were as follows: current or past history of HCC at enrollment, HCC development within 6 months after enrollment, current or past history of hepatic decompensation at enrollment, Child-Pugh B and C class, coinfection with hepatitis C and/or human immunodeficiency virus, liver transplant status, significant alcohol consumption, and insufficient clinical and laboratory data ([Supplementary Fig. 1](#s1-gnl-13-197){ref-type="supplementary-material"}).

This study was performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Boards at Severance Hospital (2018-0764-001) and at CHA Bundang Medical Center (2018-04-050). Written informed consent from enrolled patients was waived due to the retrospective nature of this study.

2. Baseline work-up and follow-up
---------------------------------

At baseline, patients provided a full medical history; underwent physical examination and routine blood chemistry; were assessed for hepatitis B e antigen (HBeAg) and its antibody, serum HBV DNA level, and α-fetoprotein (AFP) levels, underwent ultrasonography, and were screened for HCC. If no evidence of HCC was detected, patients were followed up every 6 months with ultrasonography and laboratory work-up, including AFP to screen for HCC. HBsAg and HBeAg were measured using standard enzyme-linked immunosorbent assays (Abbott Laboratories, Chicago, IL, USA). HBV DNA levels were measured using a real-time polymerase chain reaction assay (Amplicor HBV Monitor Test; Roche Diagnostics, Basel, Switzerland; detection limit approximately 20 IU/mL).

3. Antiviral therapy
--------------------

During the study, AVT was initiated based on the treatment guidelines developed by the Korean Association for the Study of the Liver.[@b13-gnl-13-197] In cases of virologic breakthrough (defined as \>1 log10 IU/mL increase in serum HBV DNA level from nadir on two consecutive tests) or genotypic mutations, rescue therapy was applied, if appropriate.

4. Diagnosis of cirrhosis and HCC
---------------------------------

Cirrhosis was diagnosed based on liver histology, ultrasonographic findings or clinical signs of portal hypertension, such as the presence of ascites, esophageal or gastric varices, and hepatic encephalopathy.[@b14-gnl-13-197] HCC was diagnosed based on radiologic findings from computed tomography or/and magnetic resonance imaging or based on histologic evidence, in accordance with the guideline of the American Association for the Study of Liver Diseases.[@b15-gnl-13-197]

5. Statistical analyses
-----------------------

Data are expressed as the mean±standard deviation, median with range, or number (%) as appropriate. Differences among continuous and categorical variables were examined for statistical significance using the Student t-test (or the Mann-Whitney U-test, if appropriate) and the chi-square test (or Fisher exact test, if appropriate), respectively. Person-years of follow-up were calculated from the date of study entry to either the onset of HCC or the last follow-up date.

Patients were censored at the time of HCC development or at the last follow-up. The incidence rate was calculated by dividing the number of patients with newly diagnosed HCC by the corresponding person-years. Cumulative HCC incidence rates were analyzed using the Kaplan-Meier method and compared with the log-rank test. To estimate independent predictors of HCC development, univariate and subsequent multivariate Cox proportional hazard regression analyses were performed. HRs and corresponding 95% confidence intervals (CIs) were used where indicated. Various multivariate logistic regression analyses were applied to determine the independent associations among HBV-related variables (HBV DNA level, HBeAg status, and alanine aminotransferase \[ALT\] level), cirrhosis, and the risk of HCC development.

All statistical analyses were performed using SPSS software version 18.0 (SPSS Inc., Chicago, IL, USA). A p-value \<0.05 was considered to indicate statistical significance.

RESULTS
=======

1. Baseline characteristics
---------------------------

Among 4,850 patients with CHB from two centers (2,442 patients from Severance Hospital, Yonsei University and 2,408 patients from CHA Bundang Medical Center, CHA University) who were considered eligible for this study, 3,007 patients were excluded according to our exclusion criteria. Finally, 1,843 patients were selected for statistical analysis (804 patients from Severance Hospital and 1,039 patients from CHA Bundang Medical Center) ([Supplementary Fig. 1](#s1-gnl-13-197){ref-type="supplementary-material"}).

The baseline characteristics of the study population at enrollment are summarized in [Table 1](#t1-gnl-13-197){ref-type="table"}. The mean age of our study population (1,063 men and 780 women) was 49.4 years. Cirrhosis was identified in 617 patients (33.5%), and 453 patients (24.6%) were HBeAg positive. The mean HBV DNA and ALT levels were 2.8 log10 IU/mL and 44.4 IU/L, respectively. A total of 645 patients (35.0%) received ongoing AVT at enrollment, which included lamivudine (n=62, 9.6%), telbivudine (n=23, 3.6%), clevudine (n=10, 1.6%), adefovir (n=89, 13.8%), entecavir (n=315, 48.8%), tenofovir (n=44, 6.8%), or a combination regimen (n=102, 15.8%).

2. Follow-up and HCC development
--------------------------------

The median follow-up period of the entire study population was 42.5 months (range, 6.1 to 51.7 months), constituting a total of 5,845 person-years. The follow-up periods of the two institutions were statistically similar (median 41.6 months vs 43.1 months, p=0.438). During follow-up, 81 patients (49 \[60.5%\] from Severance Hospital and 32 \[39.5%\] from CHA Bundang Medical Center) developed HCC (1.39% per 1 person-year). The cumulative incidence rates of HCC at 1 and 3 years were 0.6% and 3.4%, respectively. Of the 81 patients who developed HCC, 39 (48.1%) received AVT at enrollment, and 35 (43.2%) initiated AVT after enrollment. The remaining seven (8.7%) patients without AVT during the study period experienced HCC development (two with minimally increased ALT levels \[1--2× upper limit of normal\] and five with liver cirrhosis, possibly from HBeAg-negative CHB phase).

3. Comparisons of baseline characteristics according to AVT status
------------------------------------------------------------------

To investigate the reason for the similar or even higher risk of HCC development in patients with ongoing AVT at enrollment when compared with those without AVT, we compared the baseline characteristics of these two groups ([Table 2](#t2-gnl-13-197){ref-type="table"}). Patients receiving AVT at enrollment were significantly older (mean 50.3 years vs 48.9 years) and had a higher incidence of diabetes mellitus (13.3% vs 10.0%) and cirrhosis (42.8% vs 28.5%), lower AFP level (mean 4.5 ng/mL vs 6.9 ng/mL), lower HBV DNA level (mean 1.6 log IU/mL vs 3.4 log IU/mL), lower aspartate aminotransferase (AST) level (mean 28.3 IU/L vs 42.2 IU/L), lower ALT level (mean 28.2 IU/L vs 53.1 IU/L), and lower platelet count (mean 163×10^9^/L vs 179×10^9^/L) than patients not engaged in AVT at enrollment (all p\<0.05).

We also compared the baseline characteristics between patients who initiated AVT after enrollment and those naïve to AVT during the study period ([Supplementary Table 1](#s1-gnl-13-197){ref-type="supplementary-material"}). Patients who initiated AVT after enrollment were significantly more likely to have cirrhosis (42.0% vs 19.1%) and HBeAg positivity (41.5% vs 10.3%), higher AFP level (mean 10.5 ng/mL vs 4.4 ng/mL), higher HBV DNA level (mean 4.2 log IU/mL vs 2.9 log IU/mL), higher AST level (mean 62.0 IU/L vs 28.4 IU/L), higher ALT level (mean 81.3 IU/L vs 33.6 IU/L), lower serum albumin level (mean 4.3 g/dL vs 4.4 g/dL), higher total bilirubin level (mean 0.9 vs 0.8), and lower platelet count (mean 162×10^9^/L vs 192×10^9^/L) than patients naïve to AVT during the study period (all p\<0.05).

4. Association between HBV-related variables and risk of HCC development
------------------------------------------------------------------------

The HRs of HCC development by HBV-related variables (HBV DNA level, HBeAg status, and ALT level) and differently adjusted models are summarized in [Table 3](#t3-gnl-13-197){ref-type="table"}. All three variables were not significantly associated with the risk of HCC development, regardless of adjustment (all p\>0.05). When the study population was divided into two groups with and without ongoing AVT (n=645 \[35.0%\] and n=1,198 \[65.0%\], respectively), there was also no significant association between HBV-related variables and the risk of HCC development in both subgroups (all p\>0.05) ([Table 3](#t3-gnl-13-197){ref-type="table"}).

In the entire cohort, the cumulative HCC incidence rates were not significantly different according to HBV DNA level (p=0.821 by log-rank test, HBV DNA ≤100 IU/mL \[n=986, 53.5%\] vs 101--10,000 IU/mL \[n=470, 25.5%\] vs 10,001--1,000,000 IU/mL \[n=178, 9.7%\] vs \>1,000,000 IU/mL \[n=209, 11.3%\]) ([Supplementary Fig. 2A](#s1-gnl-13-197){ref-type="supplementary-material"}), HBeAg status (p=0.947 by log-rank test, positive \[n=453, 24.6%\] vs negative \[n=1,390, 75.4%\]) ([Supplementary Fig. 2B](#s1-gnl-13-197){ref-type="supplementary-material"}), and ALT level (p=0.325 by log-rank test, ≤40 IU/L \[n=1,364, 74.0%\] vs 41--80 IU/L \[n=338, 18.3%\] vs 81--400 IU/L \[n=123, 6.7%\] vs \>400 IU/L \[n=18, 1.0%\]) ([Supplementary Fig. 2C](#s1-gnl-13-197){ref-type="supplementary-material"}).

5. Association between ongoing AVT and risk of HCC development
--------------------------------------------------------------

The HRs of HCC development by ongoing AVT and differently adjusted models are summarized in [Table 4](#t4-gnl-13-197){ref-type="table"}. In the entire population, ongoing AVT did not show a significant association with the risk of HCC development after adjustments (all p\>0.05). The association between ongoing AVT and risk of HCC development was assessed in each institution ([Supplementary Table 2](#s1-gnl-13-197){ref-type="supplementary-material"}), and ongoing AVT was not associated with the risk of HCC development at Severance Hospital (n=804 \[43.6%\]) (all p\>0.05). Although ongoing AVT showed an independent positive association with a higher risk of HCC development in minimally adjusted models in the subgroup from CHA Bundang Medical Center (n=1,039 \[56.4%\]) (HR=2.265 \[95% CI, 1.113 to 4.611\] in model 1, which adjusted for age and gender, and HR=2.217 \[95% CI, 1.089 to 4.514\] in model 2, which adjusted for age, gender, and diabetes mellitus; all p\<0.05), the significance was attenuated in further models that adjusted for more covariates. The cumulative incidence rates of HCC in patients with ongoing AVT (0.9% at 1 year and 4.2% at 3 years) tended to be higher than those in patients without ongoing AVT (0.3% at 1 year and 2.8% at 3 years), but these differences did not show any statistical significance (p=0.076 by log-rank test) ([Fig. 1](#f1-gnl-13-197){ref-type="fig"}).

6. Association between cirrhosis and risk of HCC development
------------------------------------------------------------

The HRs of HCC development by cirrhosis and differently adjusted models are summarized in [Table 5](#t5-gnl-13-197){ref-type="table"}. In the entire population, cirrhosis showed a significant association with the risk of HCC development regardless of various adjustments (unadjusted HR=8.454 \[95% CI, 4.824 to 14.813\], adjusted HR=4.098 to 7.020; all p\<0.05). When the study population was stratified into two subgroups based on AVT status at enrollment, cirrhosis was a significant risk factor for HCC development in both subgroups, regardless of the adjustments ([Supplementary Table 3](#s1-gnl-13-197){ref-type="supplementary-material"}).

The association between cirrhosis and risk of HCC development was assessed at each institution ([Supplementary Table 4](#s1-gnl-13-197){ref-type="supplementary-material"}). Cirrhosis was significantly associated with the risk of HCC development at Severance Hospital regardless of adjustments (unadjusted HR=4.795 \[95% CI 2.327 to 9.883\], adjusted HR=3.380 to 4.435; all p\<0.05), except for the borderline statistical significance observed in model 5, which adjusted for age, gender, diabetes mellitus, laboratory tests, AVT at enrollment, and AVT initiation after enrollment (HR=2.228 \[95% CI, 0.966 to 5.141\]; p=0.060). In the subgroup from CHA Bundang Medical Center, cirrhosis was independently associated with the risk of HCC development regardless of adjustments (unadjusted HR=14.021 \[95% CI, 5.770 to 34.070\], adjusted HR=7.237 to 11.347; all p\<0.001).

The cumulative incidence of HCC in the subgroup with cirrhosis was significantly higher than that of the subgroup without cirrhosis (p\<0.001 by log-rank test) ([Fig. 2](#f2-gnl-13-197){ref-type="fig"}). The cumulative incidence rate of HCC in the subgroup with cirrhosis at 1 and 3 years was 1.5% and 7.6%, respectively, whereas in the subgroup without cirrhosis, the rate was 0.1% and 1.1%, respectively.

DISCUSSION
==========

In this multicenter study comprising CHB patients with heterogeneous HBV status, AVT did not significantly predict HCC development after adjusting for other variables. In addition, HBV-related variables such as HBV DNA, HBeAg, and ALT level were not associated with the risk of HCC development. In contrast, liver cirrhosis was significantly associated with the risk of HCC development regardless of adjustments (unadjusted HR=8.454, adjusted HR=4.098--7.020). Accordingly, the cumulative incidence of HCC in the subgroup with cirrhosis was significantly higher than that in the subgroup without cirrhosis.

Several studies have demonstrated a decrease in HCC development in patients with CHB who received AVT compared with historical controls who were unable to obtain AVT.[@b4-gnl-13-197],[@b8-gnl-13-197],[@b16-gnl-13-197]--[@b20-gnl-13-197] However, in some previous studies that included patients receiving AVT and those in the inactive or immune tolerant phase who did not require AVT, AVT did not show a beneficial effect in preventing HCC development. A previous study[@b21-gnl-13-197] that investigated predictors of HCC development in heterogeneous CHB cohorts showed that AVT was not significantly associated with HCC risk. By contrast, the degree of fibrotic burden, which was defined using transient elastography, was selected as an independent predictor of HCC development. In another study by Park *et al*.,[@b12-gnl-13-197] AVT was a significant predictor of HCC development, contrary to expectation, probably due to the unfavorable baseline characteristics of patients with AVT compared to those of patients without AVT; patients with AVT presented a higher body mass index, higher total bilirubin, higher AST level, lower serum albumin level, and higher degree of fibrotic burden than patients without AVT. We also investigated the influence of AVT on HCC development in a cohort with heterogeneous CHB status and found that, after adjusting for multiple variables, AVT showed no association with HCC development. More importantly, there was a trend of a higher risk of HCC development in patients receiving AVT at enrollment than in those not receiving AVT at enrollment.

Among 707 patients who did not receive AVT during the study period, seven patients developed HCC in our study. These patients who were not candidates for AVT according to Korean guidelines[@b13-gnl-13-197] had minimally elevated ALT level or liver cirrhosis, possibly due to the HBeAg-negative CHB phase, indicating the importance of careful surveillance even in patients who do not undergo AVT. Regarding this issue, several studies showed that the indications of AVT should be expanded to individuals with lower serum HBV DNA levels and/or lower serum ALT levels.[@b22-gnl-13-197],[@b23-gnl-13-197] In addition, recent studies showed that HCC or progression to cirrhosis can develop even in patients in the immune tolerance or inactive carrier phases.[@b24-gnl-13-197]--[@b26-gnl-13-197] However, no patients in the immune tolerance or inactive carrier phases developed HCC in our study, probably due to relatively small sample size of patients in these CHB phases in our study.

Because patients with worse baseline characteristics might have a higher chance of receiving AVT than those with favorable predictors such as low viral titer and normal ALT level, careful interpretation is needed regarding the influence of AVT when assessing mixed CHB cohorts. Indeed, in our cohort, compared with patients without AVT at enrollment, those with AVT had more confounding factors that could also be associated with an increased risk of HCC development, such as older age, higher incidence of cirrhosis, higher AFP level, higher total bilirubin level, and lower platelet level. The observed unfavorable characteristics in patients with AVT were quite similar to those reported by Park *et al*.,[@b12-gnl-13-197] as mentioned above. This phenomenon of inevitably imbalanced characteristics between patients with and without AVT might explain the varying influence of AVT on the risk of HCC development in heterogeneous HBV cohorts, which, in turn, suggests that cohorts with heterogeneous HBV status should be divided into subgroups with and without AVT and that the disease course of each cohort should be investigated separately.

In our study, we were able to clearly show that patients with cirrhosis had a higher risk for HCC than those without cirrhosis in a cohort with heterogeneous CHB status, regardless of AVT status. Several studies showed that appropriate AVT with potent antiviral agents cannot completely abolish the risk of HCC development. These studies also demonstrated that cirrhosis is a significant risk factor for HCC incidence during AVT.[@b8-gnl-13-197],[@b20-gnl-13-197],[@b27-gnl-13-197]--[@b30-gnl-13-197] Moreover, several reports used recently developed noninvasive imaging and serum surrogates to assess the degree of liver fibrosis and showed that fibrotic burden is a significant risk factor for HCC development.[@b31-gnl-13-197]--[@b37-gnl-13-197] A previous study by Kim *et al*.,[@b38-gnl-13-197] which used transient elastography to assess fibrotic burden, also reported a similar finding--the degree of liver fibrosis, rather than potent AVT with appropriate rescue therapy, was associated with the risk of HCC development. In another study by Kim *et al*.,[@b34-gnl-13-197] advanced fibrosis as defined by transient elastography was an important risk factor for HCC development, even in patients without clinical evidence of cirrhosis. They also showed that cirrhosis was an independent HCC risk factor in patients with and without AVT, which is consistent with the findings of our current study. Taken together, these data suggest that because patients with cirrhosis have a higher risk of HCC development regardless of AVT status, clinicians should actively assess the degree of liver fibrosis to develop an individual surveillance strategy for these patients.

In our study, well-known conventional risk factors of HCC development, such as HBV DNA level, HBeAg status, and ALT level, failed to show significant correlations with the risk of HCC development. Although these HBV-related variables have been useful in determining the disease state and in predicting clinical outcomes in patients with HBV infection until recently, this approach might be no longer appropriate in this era of active and potent AVT, especially when there is a need to predict clinical outcomes, including HCC development. Indeed, based on current guidelines, the higher risk of disease progression due to unfavorable characteristics such as high viral load and high ALT level can be significantly reduced due to the current potent AVTs,[@b2-gnl-13-197],[@b3-gnl-13-197],[@b13-gnl-13-197],[@b22-gnl-13-197] which suppress HBV DNA potently and rapidly normalize ALT. Therefore, it is not surprising that the influence of these conventional risk factors on the risk of HCC development was attenuated in our study.

We are also aware of several limitations of our study. First, our findings might have been influenced by the relatively short follow-up period (median, 42.5 months) because we tried to include patients treated with drugs with a high genetic barrier to reflect the current era of potent AVTs, including entecavir-based (48.8%) and tenofovir-based (6.8%) regimens, which were approved in Korea in 2007 and 2012, respectively. Thus, a subsequent study with a longer follow-up and with homogenous use of drugs with a high genetic barrier would be required. Second, the simple stratification of cirrhosis based on ultrasound might have biased our results. As is commonly known, the diagnostic accuracy of ultrasound for cirrhosis has been mixed. Indeed, a recent study has shown that compared to transient elastography, ultrasonographic evaluation can miss the diagnosis of early compensated cirrhosis.[@b34-gnl-13-197] Thus, further studies that use more recent and accurate noninvasive imaging surrogates to assess the stepwise increase in fibrotic burden are required to validate our results. Third, more detailed information regarding fibrotic burden based on either histology or transient elastography was not available. However, because fibrotic burden can be variable even in patients undergoing AVT, future studies with fibrotic burden-matched cohorts that compare patients with and without AVT might provide more relevant clinical implications. Finally, the baseline characteristics of patients from two institutions were significantly different. Accordingly, the proportion of patients who developed HCC was significantly different between the institutions. However, we tried to reduce the potential bias by adjusting for institutions after adjusting HBV-related variables, AVT, and cirrhosis to estimate risk of HCC development. The overall results were similar between the two institutions, which might indicate the reproducibility of our results regardless of the baseline characteristics of the study population.

In conclusion, in our study, AVT as well as HBV-related variables, including HBV DNA level, HBeAg status, and ALT level, were unexpectedly not associated with HCC development. Thus, to prevent the biased influence of AVT on the risk of HCC development, it would be better to analyze the separated cohort based on AVT and not the heterogeneous CHB cohorts in future HBV studies. Furthermore, in our study, patients with cirrhosis had a higher risk of HCC development, indicating that cirrhosis, not AVT, can predict HCC development in cohorts with heterogeneous HBV status. Our results may help clinicians apply individualized surveillance strategies according to fibrotic status in patients with CHB.
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###### 

Baseline Characteristics

  Variable                            All (n=1,843)   Yonsei University (n=804, 43.6%)   Cha University (n=1039, 56.4%)   p-value
  ----------------------------------- --------------- ---------------------------------- -------------------------------- ---------
  Demographic                                                                                                             
   Age, yr                            49.4±11.4       52.4±10.7                          47.1±11.3                        \<0.001
   Male sex                           1,063 (57.7)    443 (55.1)                         620 (59.7)                       0.051
   Diabetes mellitus                  206 (11.2)      44 (5.5)                           162 (15.6)                       \<0.001
   Cirrhosis                          617 (33.5)      379 (47.1)                         238 (22.9)                       \<0.001
  Laboratory                                                                                                              
   α-Fetoprotein, ng/mL               6.1±22.4        5.7±21.5                           6.3±23.1                         0.579
   HBeAg positivity                   453 (24.6)      154 (19.2)                         299 (28.8)                       \<0.001
   HBV DNA, log IU/mL                 2.8±2.1         2.7±2.0                            2.9±2.2                          0.021
   Aspartate aminotransferase, IU/L   37.3±57.6       33.7±43.7                          40.1±66.4                        0.013
   Alanine aminotransferase, IU/L     44.4±90.5       39.2±70.1                          48.5±103.5                       0.022
   Serum albumin, g/dL                4.4±0.4         4.3±0.3                            4.5±0.4                          \<0.001
   Total bilirubin, mg/dL             0.8±0.5         0.9±0.5                            0.8±0.4                          \<0.001
   Platelet count, 10^9^/L            174±60          168±64                             178±57                           \<0.001
   Ongoing antiviral therapy          645 (35.0)      278 (34.6)                         367 (35.3)                       0.768

Data are presented as mean±SD or number (%). HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.

###### 

Comparison of Baseline Characteristics between Patients with and without Ongoing AVT at Enrollment

  Variable                            With ongoing AVT at enrollment (n=645, 35.0%)   Without ongoing AVT at enrollment (n=1,198, 65.0%)   p-value
  ----------------------------------- ----------------------------------------------- ---------------------------------------------------- ---------
  Demographic                                                                                                                              
   Age, yr                            50.3±10.4                                       48.9±11.8                                            0.011
   Male sex                           387 (60.0)                                      676 (56.4)                                           0.152
   Diabetes mellitus                  86 (13.3)                                       120 (10.0)                                           0.036
   Cirrhosis                          276 (42.8)                                      341 (28.5)                                           \<0.001
  Laboratory                                                                                                                               
   α-Fetoprotein, ng/mL               4.5±14.1                                        6.9±25.8                                             0.009
   HBeAg positivity                   176 (27.3)                                      277 (23.1)                                           0.054
   HBV DNA, log IU/mL                 1.6±1.0                                         3.4±2.2                                              \<0.001
   Aspartate aminotransferase, IU/L   28.3±26.8                                       42.2±68.3                                            \<0.001
   Alanine aminotransferase, IU/L     28.2±31.2                                       53.1±109.0                                           \<0.001
   Serum albumin, g/dL                4.4±0.4                                         4.4±0.3                                              0.211
   Total bilirubin, mg/dL             0.9±0.5                                         0.8±0.4                                              0.901
   Platelet count, 10^9^/L            163±57                                          179±62                                               \<0.001

Data are presented as mean±SD or number (%).

AVT, antiviral therapy; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.

###### 

HRs of Hepatocellular Carcinoma Development by HBV-Related Variables and Differently Adjusted Models

  Model                               HBV DNA   HBeAg          ALT                                                           
  ----------------------------------- --------- -------------- ------- ------- -------------- ------- ------- -------------- -------
  All                                                                                                                        
   Unadjusted                         0.968     0.865--1.082   0.568   0.983   0.593--1.629   0.947   1.000   0.998--1.002   0.764
   Adjusted                                                                                                                  
    Model 1                           1.030     0.920--1.153   0.609   1.381   0.824--2.313   0.221   1.001   0.999--1.003   0.368
    Model 2                           1.031     0.920--1.154   0.712   1.379   0.823--2.311   0.222   1.001   0.999--1.003   0.364
    Model 3                           1.092     0.975--1.223   0.129   1.369   0.820--2.285   0.229   1.001   0.999--1.003   0.244
    Model 4                           1.097     0.947--1.271   0.217   1.201   0.693--2.084   0.514   1.000   0.994--1.006   0.800
    Model 5                           1.057     0.911--1.226   0.464   1.032   0.599--1.779   0.909   1.001   0.994--1.007   0.876
    Model 6                           1.059     0.913--1.227   0.451   1.046   0.606--1.803   0.873   1.000   0.993--1.007   0.734
  Without ongoing AVT at enrollment                                                                                          
   Unadjusted                         1.004     0.877--1.150   0.952   0.893   0.427--1.866   0.763   1.001   0.999--1.003   0.549
   Adjusted                                                                                                                  
    Model 1                           1.079     0.941--1.238   0.275   1.223   0.579--2.581   0.598   1.001   0.999--1.003   0.306
    Model 2                           1.080     0.941--1.238   0.274   1.222   0.579--2.581   0.598   1.001   0.999--1.003   0.305
    Model 3                           1.116     0.967--1.288   0.134   1.090   0.515--2.306   0.821   1.001   0.999--1.003   0.240
    Model 4                           1.120     0.942--1.332   0.199   0.914   0.399--2.095   0.831   1.002   0.994--1.009   0.674
    Model 5                           1.057     0.889--1.257   0.531   0.681   0.303--1.527   0.351   1.003   0.995--1.011   0.425
    Model 6                           1.059     0.891--1.260   0.514   0.702   0.313--1.573   0.390   1.002   0.994--1.010   0.617
  With Ongoing AVT at enrollment                                                                                             
   Unadjusted                         1.057     0.803--1.391   0.695   1.032   0.513--2.072   0.931   1.000   0.989--1.011   0.991
   Adjusted                                                                                                                  
    Model 1                           1.128     0.850--1.498   0.404   1.529   0.742--3.151   0.250   1.003   0.992--1.013   0.648
    Model 2                           1.126     0.847--1.496   0.415   1.522   0.738--3.139   0.255   1.002   0.992--1.013   0.664
    Model 3                           1.182     0.909--1.536   0.212   1.721   0.846--3.501   0.134   1.000   0.987--1.014   0.961
    Model 4                           1.030     0.722--1.468   0.871   1.523   0.712--3.260   0.278   0.994   0.974--1.014   0.556
    Model 5                           1.030     0.722--1.468   0.871   1.523   0.712--3.260   0.278   0.994   0.974--1.014   0.556
    Model 6                           1.029     0.721--1.470   0.874   1.517   0.708--3.250   0.283   0.994   0.974--1.014   0.567

HR, hazard ratio; HBV, hepatitis B virus; HBeAg, HBV e antigen; ALT, alanine aminotransferase; CI, confidence interval; AVT, antiviral therapy.

Model 1, age and gender; model 2, model 1 + diabetes mellitus; model 3, model 2 + cirrhosis; model 4, model 3 + α-fetoprotein, HBeAg positivity, HBV DNA, aspartate aminotransferase, alanine aminotransferase, serum albumin, total bilirubin, platelet count, and antiviral therapy AVT at enrollment; model 5, model 4 + AVT initiation after enrollment; model 6, model 5 + institution.

###### 

HRs of Hepatocellular Carcinoma Development by Ongoing Antiviral Therapy and Differently Adjusted Models

  Model        HR      95% CI         p-value
  ------------ ------- -------------- ---------
  Unadjusted   1.480   0.957--2.291   0.078
  Adjusted                            
   Model 1     1.475   0.952--2.283   0.082
   Model 2     1.472   0.951--2.280   0.083
   Model 3     1.141   0.735--1.771   0.557
   Model 4     1.356   0.819--2.245   0.236
   Model 5     1.352   0.817--2.237   0.241

HR, hazard ratio; CI, confidence interval; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus.

Model 1, age and gender; model 2, model 1 + diabetes mellitus; model 3, model 2 + cirrhosis; model 4, model 3 + α-fetoprotein, HBeAg positivity, HBV DNA, aspartate aminotransferase, alanine aminotransferase, serum albumin, total bilirubin, and platelet count; model 5, model 4 + institution.

###### 

HRs of Hepatocellular Carcinoma Development by Cirrhosis and Differently Adjusted Models (All Study Participants)

  Model        HR      95% CI          p-value
  ------------ ------- --------------- ---------
  Unadjusted   8.454   4.825--14.813   \<0.001
  Adjusted                             
   Model 1     6.957   3.957--12.231   \<0.001
   Model 2     7.020   3.992--12.347   \<0.001
   Model 3     5.257   2.795--9.885    \<0.001
   Model 4     5.117   2.754--9.733    \<0.001
   Model 5     4.337   2.301--8.177    \<0.001
   Model 6     4.095   2.148--7.807    \<0.001

HR, hazard ratio; CI, confidence interval; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; AVT, antiviral therapy.

Model 1, age and gender; model 2, model 1 + diabetes mellitus; model 3, model 3 + α-fetoprotein, HBeAg positivity, HBV DNA, aspartate aminotransferase, alanine aminotransferase, serum albumin, total bilirubin, and platelet count; model 4, model 3 + AVT at enrollment; model 5, model 4 + AVT after enrollment; model 6, model 5 + institution.
